and high-quality care, maximizing therapeutic
success with a potentially curable disease.
References
1.
BioPharm Insight. Boston, MA: Infanata; 2013. http://
www.biopharm-insight.com/biopharm/AccessPoint.
aspx?action=InfinataFrame.DisplayFrame&random_x=1827414738.
Accessed February 12, 2014.
2. Hepatitis C Information for Health Professionals. Centers for Disease
Control and Prevention Web site. http://www.cdc.gov/hepatitis/hcv/
hcvfaq.htm#a4. Updated February 10, 2014. Accessed February 10,
2014.
3. Deming P. Viral hepatitis. In: DiPiro JT, Talbert RL, Yee GC,
Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A
Pathophysiologic Approach. 8th ed. New York, NY: McGraw-Hill;
2011.
4. American Association for the Study of Liver Diseases (AASLD).
Recommendations for Testing, Managing, and Treating Hepatitis
C. http://www.hcvguidelines.org/full-report-view. Updated January
2014. Accessed February 7, 2014.
5. Dienstag JL. Chronic hepatitis. In: Longo DL, Fauci AS, Kasper DL,
Hauser SL, Jameson JL, Loscalzo J, eds. Harrison’s Principles of
Internal Medicine. 18th ed. New York: McGraw-Hill; 2012.
6. McHutchison JG, Manns M, Patel K, et al. Adherence to combination
therapy enhances sustained response in genotype-1–infected
patients with chronic hepatitis C. Gastroenterology 2002;123:106169.
7. Liang TJ, Ghany MG. Current and future therapies for hepatitis C
virus infection. N Engl J Med 2013;368:1907-17.
8. Olysio™ [package insert]. Titusville, NJ: Janssen Therapeutics, LP;
2013.
9. Sovaldi™ [package insert]. Foster City, CA: Gilead Sciences, Inc.;
2013.
10. Gilead files for U.S. approval of ledipasvir/sofosbuvir fixed-dose
combination tablet for genotype 1 hepatitis C [news release]. Foster
City, CA: Gilead Sciences, Inc; February 10, 2014. http://www.gilead.
com/news/press-releases/2014/2/gilead-files-for-us-approval-ofledipasvirsofosbuvir-fixeddose-combination-tablet-for-genotype-1hepatitis-c. Accessed February 14, 2014.
11. AbbVie demonstrates 96 percent SVR(12) in its phase III study of
treatment-experienced patients with genotype 1 hepatitis C [news
release]. North Chicago, IL: AbbVie Inc; December 10, 2013. http://
abbvie.mediaroom.com/2013-12-10-AbbVie-Demonstrates-96percent-SVR-12-in-its-Phase-III-Study-of-Treatment-ExperiencedPatients-with-Geno